Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NSD2 | O96028 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31139407 | 1.00 | ALDH1A1 (0.64) | ALDH1A1HPGDHSD17B10MEN1NSD2 | |
| SCHEMBL28325177 | 0.84 | SMN1; SMN2 (0.48) | ALDH1A1HPGDHSD17B10MAPTL3MBTL1 | |
| SCHEMBL21793377 | 0.83 | ALDH1A1 (0.53) | ALDH1A1HPGDHSD17B10MEN1NSD2 | |
| Hydrochloric Acid SCHEMBL28780309 | 0.81 | CXCL8 (0.54) | ALDH1A1MEN1KMT2AMAPTCXCL8 | |
| SCHEMBL2018214 | 0.81 | CXCL8 (0.54) | ALDH1A1MEN1KMT2AMAPTCXCL8 | |
| SCHEMBL28847313 | 0.79 | CXCL8 (0.53) | ALDH1A1MEN1KMT2AMAPTCXCL8 | |
| SCHEMBL28122217 | 0.79 | CXCL8 (0.53) | ALDH1A1MEN1KMT2AMAPTCXCL8 | |
| SCHEMBL28307658 | 0.79 | CXCL8 (0.53) | ALDH1A1MEN1KMT2AMAPTCXCL8 | |
| SCHEMBL3207752 | 0.79 | ALDH1A1 (0.66) | ALDH1A1HPGDHSD17B10MEN1NSD2 | |
| SCHEMBL8691528 | 0.79 | ALDH1A1 (0.65) | ALDH1A1HPGDHSD17B10POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352021-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-10-24 | — | — | US | disclosed |
| EP-4419529-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023069959-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-109503478-B | 2, 3-dihydro-1H-quinoline-4-ketone thiosemicarbazone derivative and preparation method and application thereof | 岭南师范学院 | 2020-04-24 | — | — | CN | disclosed |
| US-8222417-B2 | Compound having 11β-HSD1 inhibitory activity | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100179325-A1 | COMPOUND HAVING 11BETA-HSD1 INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2172453-A1 | COMPOUND HAVING 11 ß-HSD1 INHIBITORY ACTIVITY | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-0638065-B1 | A PROCESS FOR THE PREPARATION OF 3- AND/OR 5-SUBSTITUTED ANTHRANILIC ACIDS | DOWELANCO (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0638065-A1 | A PROCESS FOR THE PREPARATION OF 3- AND/OR 5-SUBSTITUTED ANTHRANILIC ACIDS. | DOWELANCO (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993022276-A1 | A PROCESS FOR THE PREPARATION OF 3- AND/OR 5-SUBSTITUTED ANTHRANILIC ACIDS | DOWELANCO (US) | 1993-11-11 | — | — | WO | disclosed |
| US-5189210-A | Process for the preparation of 3- and/or 5-substituted anthranilic acids | DOWELANCO (US) | 1993-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179325-A1 | COMPOUND HAVING 11BETA-HSD1 INHIBITORY ACTIVITY | HSD11B1, CYP4A11, HSD11B2 | ALDH1A1 289/4885HPGD 644/4885HSD17B10 42/4885 |
| US-20240352021-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | ALDH1A1 2865/4885HPGD 1650/4885HSD17B10 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.